Partner Content Partner Content Factors behind $2,500 million Photorejuvenation Devices Mark... Photorejuvenation Devices Market to hit $2.5bn by 2025
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.
